Market Overview

Morphic Therapeutic to Present at 37th Annual J.P. Morgan Healthcare Conference


Morphic Therapeutic, a biotechnology company developing a new generation
of oral integrin therapies, announced today that the company will
present at the 37th Annual J.P. Morgan Healthcare Conference
in San Francisco on Wednesday, January 9, 2019.

Praveen Tipirneni, M.D., president and CEO of Morphic, will provide an
overview of the company, its innovative platform for designing integrin
oral inhibitors, and anticipated milestones in 2019.

Morphic is developing highly differentiated molecules for the treatment
of autoimmune diseases, fibrotic diseases, and cancer. In 2018, Morphic
announced the completion of a $80 million Series B financing and entered
into a research and development collaboration with AbbVie designed to
advance a number of Morphic's oral integrin therapeutics for
fibrosis-related indications.

Presentation details

Date: Wednesday, January 9, 2019
Time: 11:00 a.m. PT
Westin St. Francis, Elizabethan D

About Morphic Therapeutic

Morphic Therapeutic is a biotechnology company developing a new
generation of oral integrin therapies. Drawing on integrin biology
breakthroughs from the lab of noted entrepreneur and scientific founder
Tim Springer, Morphic has developed an exclusive platform to build on
these discoveries, complemented by a partnership with computational
chemistry leader Schrödinger, Inc., that facilitates the rapid and
iterative design of clinical candidates. For more information, visit

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at